GeneDx to Participate in Upcoming Investor Conferences in June
Get Alerts WGS Hot Sheet
Join SI Premium – FREE
STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June:
- Jefferies Healthcare Conference
Presentation on Wednesday, June 7, 2023, at 4:00 p.m. ET
- 44th Annual Goldman Sachs Global Healthcare Conference
Fireside chat on Monday, June 12, 2023, at 12:20 p.m. ET (9:20 a.m. PT)
A live and archived webcast of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
About GeneDx
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest, rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
Investor Relations Contact:
Tricia Truehart
[email protected]
Media Contact:
Maurissa Messier
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hawk Law Group’s Hawk Helps Hosts Third Annual Bookbag Bash, Providing Back-to-School Supplies to More Than 500 Augusta-Area Students
- Comedian Mariza Brussolo Named 2026 Best of Florida Regional Winner
- BNB Price Prediction 2026 Points to $770 But Whales Chasing Bigger Returns Are Filling Pepeto Before Listing
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Goldman Sachs, Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share